Group 1 - The Hang Seng Index rose by 1.55% at the close, with significant gains in the consumer sector leading the market [1] - The consumer sector experienced a notable increase of 2.35%, with stocks like Mixue Group up by 8.98%, Pop Mart up by 8.11%, and Gu Ming up by 7.05% [3] - Other consumer stocks such as Haidilao, China Resources Beer, and Miniso also saw gains exceeding 4% [3] Group 2 - The internet sector rebounded, closing up by 1.26%, with Tencent Holdings increasing by 2.44%, Kuaishou by 2.27%, and Alibaba by 2.06% [3] - Other internet stocks like SenseTime, Meituan, and Baidu also recorded gains above 1% [3] Group 3 - The healthcare sector showed weak consolidation but had some intraday movements, closing up by 1.11% [3] - Notable healthcare stocks included JD Health, which rose by 3.28%, CSPC Pharmaceutical by 2.71%, and BeiGene by 2.63% [3] - Other healthcare stocks such as Hansoh Pharmaceutical and WuXi Biologics also saw gains above 1% [3]

Core Viewpoint - The current adjustment in the innovative drug sector may still be in a bottoming phase, with mixed performance observed in the Hong Kong Stock Connect Innovative Drug ETF (520880) since November, indicating a lack of sustained momentum [1][5]. Fund Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has seen a significant increase in both share count and fund size, with the fund size surpassing 2 billion yuan for the first time on November 3, marking a 392% increase since its launch on July 7 [3]. - As of November 10, the fund's share count reached 3.784 billion, setting a new record since its inception [3]. Market Analysis - The current market adjustment has been substantial in both time and price, with historical data indicating that the average correction duration for the innovative drug index is 30-40 days, with a typical decline of around 20% [5]. - Recent performance of leading innovative drug companies, such as BeiGene and CanSino Biologics, has shown strong earnings, suggesting a continued positive trend in the industry [5]. Investment Strategy - The fund manager emphasizes that the innovative drug market may soon rebound, suggesting that the current phase presents a high probability of success for investors [5]. - The upcoming year-end is expected to be an active period for mergers and acquisitions in the U.S. biopharmaceutical sector, along with the JPMorgan Healthcare Conference in early January, which could serve as catalysts for the market [6]. ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) is the first ETF tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three key advantages: it is purely focused on innovative drugs, has a high concentration of leading companies, and offers better risk control by reducing the weight of less liquid stocks [6][7]. - The top ten holdings in the ETF account for over 71% of the total weight, highlighting the dominance of leading companies in the innovative drug sector [8].

Core Insights - The Hong Kong Innovative Drug ETF (159567) closed down 0.48% on November 11, with a trading volume of 854 million yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of November 10, 2024, the fund's latest share count was 9.675 billion, with a total size of 8.015 billion yuan, reflecting a significant increase in both share count and size compared to the previous year [1] Fund Performance - The fund's share count increased by 2347.04% and its size increased by 2021.31% from 3.95 million shares and 378 million yuan on December 31, 2024 [1] - Over the past 20 trading days, the cumulative trading amount reached 24.964 billion yuan, with an average daily trading amount of 1.248 billion yuan [1] - Year-to-date, the cumulative trading amount for 207 trading days was 244.556 billion yuan, with an average daily trading amount of 1.181 billion yuan [1] Fund Management - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 65.68% during the management period [2] - The fund's top holdings include companies such as BeiGene, CanSino Biologics, Innovent Biologics, and others, with significant percentages of the portfolio allocated to these stocks [2] - The largest holdings by percentage include BeiGene at 10.62%, CanSino Biologics at 10.55%, and Innovent Biologics at 10.21% [2]

Group 1 - The Hong Kong Stock Connect Innovation Drug ETF (159570) experienced a slight decline of 0.41% on November 11, with a total trading volume exceeding 1.5 billion yuan, marking a continuous inflow of over 1.5 billion yuan in the last 10 days [1] - As of November 10, the latest scale of the Hong Kong Stock Connect Innovation Drug ETF (159570) surpassed 21.5 billion yuan, maintaining a leading position in terms of scale and liquidity [1] - The ETF has seen a significant increase in its net inflow, with a total of over 1.5 billion yuan in the past 10 days, indicating strong investor interest [1] Group 2 - The innovative drug sector has shown outstanding performance, with listed companies in this sector achieving a total revenue of 8.012 billion yuan in the first three quarters of 2025, representing a year-on-year growth of 23.34% [3] - In Q3 2025, the innovative drug sector's listed companies reported a total revenue of 3.154 billion yuan, reflecting a year-on-year increase of 33.59% and a quarter-on-quarter growth of 23.75% [3] - The net profit attributable to shareholders for the innovative drug sector in Q3 2025 was -1.138 billion yuan, which is a year-on-year narrowing of 22.96% and a quarter-on-quarter narrowing of 26.01% [3] Group 3 - BeiGene has raised its full-year revenue guidance for 2025, now expecting revenue between 36.2 billion yuan and 38.1 billion yuan, driven by significant growth in product revenue and improved operational efficiency [6] - For the first three quarters of 2025, BeiGene reported revenue of 27.595 billion yuan, a year-on-year increase of 44.2%, surpassing the total revenue of 27.21 billion yuan for the entire previous year [6] - The growth in revenue is attributed to the leading position of its product, Brukinsa (Zebutinib), in the U.S. market and its continued expansion in Europe and other key global markets [6] Group 4 - The recent medical insurance negotiations involved 120 domestic and foreign enterprises, with 127 drugs participating in the basic medical insurance drug directory negotiations and 24 drugs in the commercial insurance innovative drug directory price negotiations [7] - The results of the medical insurance negotiations are expected to be announced in early December, with the new drug directory set to be implemented on January 1, 2026 [7] - This year marks the first introduction of an innovative drug directory, with a new price negotiation mechanism that facilitates coordination between pharmaceutical companies and commercial insurance [8]

流动性方面，港股创新药精选ETF盘中换手7.74%，成交4223.87万元。拉长时间看，截至11月10日，港股创新药精选ETF近1年日均成交1.20亿元。 据报道，11月10日，华润三九公告，与琅钰集团、Bioproject 达成重磅合作，拿下发作性睡病创新药铧可思(替洛利生片)在中国大陆开发与商业化权益。华 润三九这款创新药的获得，不仅将为患者带来安全治疗新选择，更标志着华润三九在罕见病赛道的布局迈出关键一步。 消息方面，近日，第76届美国肝病研究协会（AASLD）年会在美国华盛顿开幕。由上海贺普药业研发的乙肝创新药贺普拉肽临床研究取得突破性进展，以 大会报告形式公布了治疗慢性乙肝II期随机双盲临床试验结果。据介绍，该创新药通过独特的病毒进入阻断独特机制，在II期临床试验中显示可逆转"大三 阳"乙肝患者对干扰素治疗的耐药性，在部分患者实现cccDNA清除，达到国际公认乙肝治愈最高标准-灭菌性治愈（sterilising cure）。 截至2025年11月11日 14:02，恒生港股通创新药精选指数下跌0.94%。成分股方面涨跌互现，联邦制药领涨1.92%，MIRXES-B上涨1.74%，三生制药上涨 0.9 ...

Investment Rating - The report does not explicitly state an investment rating for the diabetes drug industry Core Insights - The diabetes drug market is experiencing significant innovation, particularly with GLP-1 receptor agonists, which have seen advancements in long-acting and humanized formulations [3] - The global diabetes-related healthcare expenditure has surpassed $1 trillion, indicating a growing financial burden on healthcare systems [16] - China is facing a severe diabetes crisis, with 148 million adults diagnosed and a significant number of pre-diabetic individuals [12] Summary by Sections New Drug Approvals - In 2025, several innovative diabetes drugs were approved in China, including: - Eysuparaglutide α (怡诺轻), a long-acting GLP-1 receptor agonist [2] - Ploglitin tablets (善泽平), a new oral DPP-4 inhibitor [2] - Masitide injection (信尔美), the first dual receptor agonist for GCGR/GLP-1R globally [2][3] Drug Mechanisms and Innovations - The report highlights the importance of dual receptor agonism in metabolic disease treatment, with Masitide providing both appetite suppression and liver fat metabolism benefits [3] - Combination formulations, such as Dapagliflozin and Metformin, enhance treatment adherence by optimizing drug release and minimizing gastrointestinal side effects [4] Market Trends - Traditional diabetes medications like Metformin and Sulfonylureas are experiencing declining sales, while newer drugs like GLP-1 agonists and SGLT-2 inhibitors are seeing significant growth [8] - The retail market for diabetes medications in China exceeded 13 billion yuan in 2024, with a nearly 9% year-on-year growth in Q1 2025 [22] Global Diabetes Statistics - The number of diabetes patients aged 20-79 is projected to rise from 588.7 million in 2024 to 852.5 million by 2050 [11] - In 2024, China had 148 million adults with diabetes, highlighting the urgent need for effective management strategies [12] Healthcare Expenditure - The United States leads in diabetes-related healthcare spending at $404.5 billion, followed by China at $168.9 billion [15] - China's per capita diabetes-related healthcare expenditure is only $236, indicating a disparity in healthcare resource allocation [18]

Core Viewpoint - The A+H pharmaceutical assets have shown a significant rebound, with major ETFs in the sector experiencing gains of over 1% on November 10, indicating a positive market sentiment towards the healthcare and pharmaceutical sectors [1][2][4]. Group 1: ETF Performance - The largest medical ETF in A-shares (512170) rose by 1.66%, closing at its intraday high with a trading volume of 504 million yuan, and has seen a net subscription of approximately 480 million yuan over the past week [2][4]. - The only drug ETF (562050) increased by 1.43%, with a trading volume of 12.47 million yuan, successfully surpassing the 5-day and 10-day moving averages [2][4]. - The Hong Kong Stock Connect innovative drug ETF (520880) gained 1.28%, with a trading volume of 351 million yuan, and 33 out of the 37 covered innovative drug companies saw their stocks rise [6][7]. Group 2: Market Dynamics - The A-share pharmaceutical sector is on an upward trend, with significant gains from key stocks such as Ji'an Medical and Aier Eye Hospital, among others [2][4]. - The recent adjustments in the Hong Kong Stock Connect innovative drug ETF were attributed to a decline in sentiment and profit-taking, but the underlying fundamentals remain strong [9]. - Analysts expect investment sentiment in the sector to stabilize with the increase of industry catalysts, including academic conferences and favorable policies [9]. Group 3: Investment Recommendations - Future investments in the pharmaceutical sector should focus on the clinical value and needs of patients, particularly in the innovative drug industry and related sectors [9]. - The Hong Kong Stock Connect innovative drug ETF (520880) is recommended for long-term investment, with a balanced allocation suggested between innovative drugs and underperforming sectors like medical devices and services [9][10]. - The medical ETF (512170) is noted for its significant scale of 25.6 billion yuan, making it the largest in the market, while the drug ETF (562050) is recognized as the only ETF tracking the pharmaceutical index [11].

Market Overview - The Shanghai Composite Index rose by 0.53% to return above 4000 points, while the ChiNext Index fell by 0.92% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 2.17 trillion yuan, an increase of 1.754 billion yuan compared to the previous day [1] Sector Performance - The consumer sector saw significant gains, with the Food ETF (515710) surging by 3.64%, the Pension ETF (516560) increasing by 2.54%, and the Consumer Leader ETF (516130) rising by 2.14% [2][5] - The AI computing sector experienced a downturn following the announcement of the Kimi K2 Thinking open-source model, with the ChiNext AI ETF (159363) and the Sci-Tech AI ETF (589520) declining by 0.46% and 1.19%, respectively [1] Economic Indicators - The National Bureau of Statistics reported that the Consumer Price Index (CPI) rose by 0.2% year-on-year in October, reversing a decline from September, while the Producer Price Index (PPI) showed a narrowing year-on-year increase [7] - Analysts noted that the core CPI's growth indicates a stabilization in price levels, suggesting a recovery in demand [2][7] Investment Strategies - According to Industrial Securities, the A-share market is currently positioned for dual-line investment, focusing on cyclical sectors such as chemicals, consumption, and agriculture, while also emphasizing strong industrial trends represented by AI computing [2] - The Food ETF (515710) is highlighted as a favorable investment opportunity due to its low valuation, with a price-to-earnings ratio of 20.59, placing it at a low historical percentile [8][9] Hong Kong Market Dynamics - The Hong Kong market saw the Hang Seng Index and the Hang Seng Tech Index both rise over 1%, driven by continuous inflows from southbound funds and favorable valuations of quality assets [3] - The launch of the Hong Kong Automobile 50 ETF (520783) is noteworthy, as it includes major players in the smart driving sector, providing a convenient investment tool for automotive leaders [3] Sector-Specific Insights - The food and beverage sector has attracted significant capital, with over 100 billion yuan in net inflows recently, indicating strong investor interest [7][8] - The pharmaceutical sector is also showing signs of recovery, with major ETFs in this space experiencing gains, reflecting a broader market rebound [18][25]

Group 1 - The board meeting of the company is scheduled for November 20, 2025, to approve the unaudited third-quarter results for the nine months ending September 30, 2025 [1]

（股份代號：1093） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （於香港註冊成立之有限公司） 代表董事會 石藥集團有限公司 主席 蔡東晨 香港，2025年11月10日 於 本 公 告 日 期 ， 董 事 會 包 括 執 行 董 事 蔡 東 晨 先 生 、 張 翠 龍 先 生 、 王 振 國 先 生 、 王 懷 玉 先 生 、 李 春 雷 博 士 、 姚 兵 博 士 、 蔡 鑫 先 生 及 陳 衛 平 先 生 ； 及 獨 立 非 執 行 董 事 王 波 先 生 、 CHEN Chuan先生、王宏廣教授、歐振國先生、羅卓堅先生及李泉女士。 董事會召開日期 石 藥 集 團 有 限 公 司（「 本 公 司 」）宣 布 ， 本 公 司 董 事 會（「 董 事 會 」）會 議 將 於 2025 年 11 月 20 日 （ 星期四 ）舉行，藉以（ 其中包括 ...